3,3-Difluoropiperidine carbamate heterocyclic compounds as NR2 BNMDA receptor antagonists

摘要

Chemical entities of formula (I), wherein R ¹ and Z are defined herein, are disclosed as NR2B subtype selective receptor antagonists. Pharmaceutical compositions comprising a chemical entity of formula (I), and various diseases and disorders associated with NR2B antagonism, eg, diseases and disorders of the CNS such as depression, chemical entities of formula (I) Also disclosed are methods of treating by administering. The present invention provides, among other things, an NR2B receptor antagonist with improved pharmacokinetic performance, oral activity, cardiovascular safety and one or more points exemplified by in vitro and in vivo therapeutic safety index measures. Address the need.